Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The offers underline Novo Nordisk’s interest in expanding beyond diabetes and into the rare diseases market.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.
Rumors that Acorda was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
The nearly 100-year-old medical-device business manufactures prosthetics and orthotics such as foot inserts and knee braces.
The listing of a minority of the unit, which makes X-ray and MRI machines, is set to take place in the first half of 2018.
Three biotech companies want to start out the new year with a new start.
Both companies are noted for growth through acquisition, and 2017 has been a very big year for LabCorp.
The group has bought 11 businesses in the past seven years.